...
首页> 外文期刊>IIC:International review of intellectual property and competition law >'Bayer Pharma' Decision of the European Court of Justice (Third Chamber) 12 September 2019 - Case No. C-688/17
【24h】

'Bayer Pharma' Decision of the European Court of Justice (Third Chamber) 12 September 2019 - Case No. C-688/17

机译:欧洲法院(第三庭)的``拜耳医药''裁决-案例号C-688 / 17

获取原文
获取原文并翻译 | 示例

摘要

Article 9(7) of Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004 on the enforcement of intellectual property rights, in particular, the concept of 'appropriate compensation' referred to in that provision, must be interpreted as not precluding national legislation which provides that a party shall not be compensated for losses which he has suffered due to his not having acted as may generally be expected in order to avoid or mitigate his loss and which, in circumstances such as those in the main proceedings, results in the court not making an order for provisional measures against the applicant obliging him to provide compensation for losses caused by those measures even though the patent on the basis of which those had been requested and granted has subsequently been found to be invalid, to the extent that that legislation permits the court to take due account of all the objective circumstances of the case, including the conduct of the parties, in order, inter alia, to determine that the applicant has not abused those measures.
机译:欧洲议会和理事会于2004年4月29日颁布的关于知识产权实施的第2004/48 / EC号指令第9(7)条,特别是该条款中提及的“适当补偿”的概念解释为不排除国家法律,该法律规定,当事方不得因未采取为避免或减轻其损失而普遍预期的行为而遭受的损失,并且在某些情况下(例如,在主要诉讼程序中,结果导致法院没有下达针对申请人的临时措施的命令,即使该专利后来被要求和授予的依据无效,但该申请人有义务要求申请人赔偿这些措施所造成的损失,只要该法律允许法院适当考虑此案的所有客观情况,包括当事方的行为,尤其是确定申请人没有滥用这些措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号